
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral syrup containing oxybutynin chloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing oxybutynin are listed in syrup, tablet, patch and solution forms.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Oxybutynin is an antimuscarinic bladder antispasmodic that compounding pharmacies prepare by prescription in oral, intravesical and other forms.
Oxybutynin chloride is an anticholinergic, antimuscarinic drug. It blocks acetylcholine at muscarinic receptors on bladder smooth muscle and has a direct antispasmodic effect, which relaxes the bladder. Oxybutynin chloride tablets (for example Teva) are FDA-approved for symptoms of bladder instability in uninhibited or reflex neurogenic bladder, such as urgency, frequency, leakage and urge incontinence. Extended-release tablets are approved for overactive bladder and for children 6 years and older with detrusor overactivity from a neurological condition such as spina bifida, and the Oxytrol patch is approved for overactive bladder in men, with a version for women sold over the counter. A syrup is also manufactured. A prescriber may order oxybutynin compounded when a patient needs a strength or dosage form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Oxybutynin has no boxed warning. Do not take it if you have urinary retention, gastric retention or other severe slowing of the gut, uncontrolled narrow-angle glaucoma, or an allergy to it. Swelling of the face, lips, tongue or throat (angioedema) has been reported, sometimes after the first dose; get emergency help if it happens. It can cause confusion, hallucinations, agitation and drowsiness, especially in the first months or after a dose increase, and it can make it harder for your body to cool down in hot weather. Other anticholinergic drugs add to dry mouth, constipation and drowsiness, and ketoconazole and other CYP3A4 inhibitors can raise its levels. Safety in pregnancy has not been established. LactMed has no breastfeeding data and notes that long-term use might reduce milk production. Talk to your prescriber or pharmacist about side effects.
Oxybutynin competitively blocks M1, M2 and M3 muscarinic receptors (StatPearls) and has a direct antispasmodic effect; on rabbit detrusor it showed one fifth the anticholinergic activity of atropine but four to ten times the antispasmodic activity (Teva label). After oral tablets, peak levels occur within an hour, absolute bioavailability is about 6% (range 1.6% to 10.9%), and plasma levels fall with a half-life of about 2 to 3 hours. Volume of distribution is 193 L and protein binding exceeds 99%, mainly to alpha-1 acid glycoprotein. CYP3A4 in the liver and gut wall forms the active metabolite desethyloxybutynin, and under 0.1% is excreted unchanged; ketoconazole raised levels 3 to 4 fold. Labeled indications: tablets for neurogenic bladder symptoms; extended-release tablets for overactive bladder and pediatric neurogenic detrusor overactivity; Oxytrol for overactive bladder in men. StatPearls describes intravesical instillation and rectal suppository use, and off-label use for primary focal hyperhidrosis and catheter or stent-related bladder spasm. Dosing is per prescriber. Monitor anticholinergic CNS effects, urinary retention, heat intolerance and angioedema; StatPearls advises caution in older adults and in dementia treated with cholinesterase inhibitors. Oxybutynin is not a controlled substance.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup provided, not a household spoon. Take it by mouth as directed on the label. Rinse the measuring device and recap the bottle after each dose.
Syrups are aqueous preparations. Under USP <795>, a preserved syrup usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Your label shows whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally